These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 7438324

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Non-randomized study on the effects of preoperative radiotherapy and daily administration of low-dose cisplatin against those of radiotherapy alone for oral cancer--effects on local control, control of metastases, and overall survival].
    Kurita H, Ohtsuka A, Kobayashi H, Kurashina K, Shikama N, Oguchi M.
    Gan To Kagaku Ryoho; 2000 Jan; 27(1):59-64. PubMed ID: 10660734
    [Abstract] [Full Text] [Related]

  • 23. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
    Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L.
    Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
    [Abstract] [Full Text] [Related]

  • 24. Radical irradiation and misonidazole for T2 grade III and T3 bladder cancer: 2 year follow-up.
    Abratt RP, Barnes DR, Hammond JA, Sarembok LA, Tucker RD, Williams AM.
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1719-20. PubMed ID: 6384160
    [Abstract] [Full Text] [Related]

  • 25. The Cambridge glioma trial of misonidazole and radiation therapy with associated pharmacokinetic studies.
    Bleehen NM.
    Cancer Clin Trials; 1980 Sep; 3(3):267-73. PubMed ID: 7002338
    [Abstract] [Full Text] [Related]

  • 26. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
    Dische S, Saunders MI, Flockhart IR.
    Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
    [Abstract] [Full Text] [Related]

  • 27. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA, Hoffman PC, Drinkard LC, Watson S, Samuels BL, Golomb HM, Vokes EE.
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [Abstract] [Full Text] [Related]

  • 28. Bone marrow toxicity of total-body irradiation combined with radiosensitizers.
    Shields AF, Applebaum FR, Graham T, Deeg HJ, Allalunis-Turner J, Chapman JD, Storb R.
    Radiat Res; 1989 Nov; 120(2):364-9. PubMed ID: 2533359
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study].
    Chauvet B, Félix-Faure C, Davin JL, Berger C, Vincent P, Reboul F.
    Cancer Radiother; 1998 Apr; 2 Suppl 1():77s-81s. PubMed ID: 9749084
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL, Shipley WU, Kaufman DS, Zehr EM, Heney NM, Althausen AF, McGovern FJ.
    J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
    [Abstract] [Full Text] [Related]

  • 33. [Infiltrating cancer of the bladder: can radiochemotherapy be an alternative to cystectomy?].
    Chrétien Y, Mejean A, Durdux C, Dufour B, Housset M.
    J Urol (Paris); 1996 Nov; 102(1):3-8. PubMed ID: 8763598
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
    Masunaga S, Uto Y, Nagasawa H, Hori H, Nagata K, Suzuki M, Kinashi Y, Ono K.
    Anticancer Res; 2006 Nov; 26(2A):1261-70. PubMed ID: 16619533
    [Abstract] [Full Text] [Related]

  • 35. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
    Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ, Toonkel LM, Zietman AL, Tanguay S, Sandler HM.
    Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
    [Abstract] [Full Text] [Related]

  • 36. Plasma concentrations of misonidazole.
    Notter G, Rylander U, Turesson I.
    Strahlentherapie; 1980 Apr; 156(10):714-8. PubMed ID: 7434379
    [Abstract] [Full Text] [Related]

  • 37. A prospective randomised trial of radiation with or without oral and intravesical misonidazole for bladder cancer.
    Abratt RP, Craighead P, Reddi VB, Sarembock LA.
    Br J Cancer; 1991 Nov; 64(5):968-70. PubMed ID: 1931628
    [Abstract] [Full Text] [Related]

  • 38. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
    Lin CC, Hsu CH, Cheng JC, Huang CY, Tsai YC, Hsu FM, Huang KH, Cheng AL, Pu YS.
    Int J Radiat Oncol Biol Phys; 2009 Oct 01; 75(2):442-8. PubMed ID: 19307067
    [Abstract] [Full Text] [Related]

  • 39. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
    Vokes EE, Haraf DJ, Brockstein BE, Weichselbaum RR.
    Semin Radiat Oncol; 1999 Apr 01; 9(2 Suppl 1):70-6. PubMed ID: 10210543
    [Abstract] [Full Text] [Related]

  • 40. Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
    Choy H, Yee L, Cole BF.
    Semin Oncol; 1995 Dec 01; 22(6 Suppl 15):38-44. PubMed ID: 8643969
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.